Diabetic Nephropathy Market (By Mode of Treatment: Drug Modifying Therapies, and Others; By Geography: North America, Europe, Asia-Pacific and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024

  • Product Code:
    RP-ID-10325506
  • Published Date:
    17 Jul 2021
  • Region:
    Global
  • Pages:
    151
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-50

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

Global Diabetic Nephropathy Market is estimated to reach $3,826 million by 2024; growing at a CAGR of 5.9% from 2016 to 2024. Diabetic nephropathy involves damage of kidney due to the presence of diabetic mellitus. It is a progressive kidney disease majorly caused due to occurrence if persistent proteinuria in diabetic patients. It affects people suffering from type1 and type2 diabetes. Diabetic nephropathy comprises of 5 stages, with the final being end-stage renal disease (ESRD). Patient affected by diabetic nephropathy shows symptoms of weakness, vomiting, leg swelling, high blood pressure, nausea, high albumin secretion in urine, and high level of blood urea nitrogen. Diabetic nephropathy affects around 40% of people suffering from type1 and type2 diabetics. Moreover, it is also capable of increases the chances of cardiovascular mortality. Regular awareness programs are being initiated by various government and NGOs which aids in inculcating the knowledge of preventive measures and treatments among diabetes population.

The global diabetic nephropathy market is driven by rising obesity and diabetes among population, rise in number of people suffering from kidney diseases, growing awareness and rising investments in research and development. Though, longer duration for drug approvals and government regulations may limit the growth in forecasted period. Additionally, rising awareness and demand for combination therapies might provide opportunities for the market.

The global diabetic nephropathy market is classified into mode of treatment and geography. Mode of treatment is bifurcated into drug modifying therapies (renin inhibitors, connective tissue growth factor inhibitor (CTGF), angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blockers (ARBs), monocyte chemoattractant proteins (MCP) inhibitors, diuretics, G protein-coupled receptors (GPCRs), calcium channel blockers (CCBs), antioxidant inflammation modulator (AIM), endothelin-A receptors antagonist (ETAR), and others) and others.

By geography, the market has been bifurcated into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, Mexico are covered under North America wherein Europe covers UK, Germany, France Italy, and others. Asia-Pacific covers China, Japan, India, South Korea, and others. RoW covers South America, Middle East, and Africa.

Key players in the market include Mallinckrodt Pharmaceuticals, Bayer AG, Mitsubishi Tanabe Pharma Corporation, GenKyoTex S.A., Novartis AG, Eli Lilly and Company, Mesoblast Ltd., Ampio Pharmaceuticals Inc., Reata Pharmaceuticals, and ChemoCentryx Inc., among others.

The key takeaways from the report:
The report will provide a detailed analysis of Global Diabetic Nephropathy Market with respect to major segments such as mode of treatment and geography
The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
An exhaustive regional analysis of Global Diabetic Nephropathy s Market from 2015 to 2024 will be included in the report
Profile of the key players in the Global Diabetic Nephropathy Market will be provided, which include key financials, product & services, new developments and business strategies
Scope of the Global Diabetic Nephropathy Market:
Mode of Treatment Segments
Drug Modifying Therapies
Renin Inhibitors
Connective Tissue Growth Factor Inhibitor (CTGF)
Angiotensin-Converting Enzyme (ACE) Inhibitor
Angiotensin Receptor Blockers (ARBs)
Monocyte Chemoattractant Proteins (MCP) Inhibitors
Diuretics
G Protein-Coupled Receptors (GPCRs)
Calcium Channel Blockers (CCBs)
Antioxidant Inflammation Modulator (AIM)
Endothelin-A Receptors Antagonist (ETAR)
Other Drug Modifying Therapies
Other Mode of Treatments
Geography Segments
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Other
Asia-Pacific
China
Japan
India
South Korea
Others
RoW
South America
Middle East
Africa


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  •  Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Table of Contents
Chapter 1: Prefix
1.1. Market Scope
1.2. Report Description
1.3. Research Methodology
1.3.1. Primary Research
1.3.2. Secondary Research
1.3.3. In-house Data Modeling
Chapter 2: Executive Summary
Chapter 3: Market Outline
3.1. Market Inclination, Trend, Outlook and Viewpoint
3.2. Market Share Analysis: Company's Competitive Scenario
3.3. Value Chain Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Impact Analysis
3.4.2. Restraints
3.4.2.1. Impact Analysis
3.4.3. Opportunities
3.5. Porter's five forces analysis
3.5.1. Factors Impact Analysis
Chapter 4: Diabetic Nephropathy Market by Mode of Treatment: Market Size and Forecast, 2015-2024
4.1. Overview
4.2. Drug Modifying Therapies (DMT)
4.2.1. Current Trend and Analysis
4.2.2. Market Size and Forecast
4.2.3. Angiotensin-Converting Enzyme (ACE) Inhibitor
4.2.3.1. Market Size and Forecast
4.2.4. Angiotensin Receptor Blockers (ARBs)
4.2.4.1. Market Size and Forecast
4.2.5. Diuretics
4.2.5.1. Market Size and Forecast
4.2.6. Calcium Channel Blockers (CCBs)
4.2.6.1. Market Size and Forecast
4.2.7. Renin Inhibitors
4.2.7.1. Market Size and Forecast
4.2.8. Connective Tissue Growth Factor Inhibitor (CTGF)
4.2.8.1. Market Size and Forecast
4.2.9. Antioxidant Inflammation Modulator (AIM)
4.2.9.1. Market Size and Forecast
4.2.10. Monocyte Chemoattractant Proteins (MCP) Inhibitors
4.2.10.1. Market Size and Forecast
4.2.11. Endothelin-A Receptors Antagonist (ETAR)
4.2.11.1. Market Size and Forecast
4.2.12. G Protein-Coupled Receptors (GPCRs)
4.2.12.1. Market Size and Forecast
4.2.13. Other Drug Modifying Therapies
4.2.13.1. Market Size and Forecast
4.3. Other Drug Modifying Therapies
4.3.1. Current Trend and Analysis
4.3.2. Market Size and Forecast
Chapter 5: Diabetic Nephropathy Market by Geography: Market Size and Forecast, 2015-2024
5.1. Overview
5.2. North America
5.2.1. Current Trend and Analysis
5.2.2. Market Size and Forecast
5.2.3. US
5.2.3.1. Market Size and Forecast
5.2.4. Canada
5.2.4.1. Market Size and Forecast
5.2.5. Mexico
5.2.5.1. Market Size and Forecast
5.3. Europe
5.3.1. Current Trend and Analysis
5.3.2. Market Size and Forecast
5.3.3. UK
5.3.3.1. Market Size and Forecast
5.3.4. Germany
5.3.4.1. Market Size and Forecast
5.3.5. France
6.3.5.1. Market Size and Forecast
5.3.6. Italy
6.3.6.1. Market Size and Forecast
5.3.6. Others
5.3.6.1. Market Size and Forecast
5.4. Asia-Pacific
5.4.1. Current Trend and Analysis
5.4.2. Market Size and Forecast
5.4.3. China
5.4.3.1. Market Size and Forecast
5.4.4. India
5.4.4.1. Market Size and Forecast
5.4.5. Japan
5.4.5.1. Market Size and Forecast
5.4.6. South Korea
5.4.6.1. Market Size and Forecast
5.4.6. Others
5.4.6.1. Market Size and Forecast
5.5. RoW
5.5.1. Current Trend and Analysis
5.5.2. Market Size and Forecast
5.5.3. Middle East
5.5.3.1. Market Size and Forecast
5.5.4. South America
5.5.4.1. Market Size and Forecast
5.5.5. Africa
5.5.5.1. Market Size and Forecast
Chapter 6: Company Profiles
6.1. Bayer AG
6.2. Novartis AG
6.3. Eli Lilly and Company
6.4. Mallinckrodt Pharmaceuticals
6.5. Mitsubishi Tanabe Pharma Corporation
6.6. Mesoblast Ltd.
6.7. Ampio Pharmaceuticals Inc.
6.8. Reata Pharmaceuticals
6.9. GenKyoTex S.A.
6.10. ChemoCentryx Inc.

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

0

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports